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Human leukocyte antigen (HLA) alleles have been implicated as risk factors for immune-
mediated adverse drug reactions. We recently reportd a strong association between HLA-
A*32:01 and vancomycin-induced drug reaction with eosinophilia and systemic symptoms 
(DRESS). Identification of individuals with the risk allele prior to or shortly after the 
initiation of vancomycin therapy is of great clinical importance to prevent morbidity and 
mortality, improve drug safety and antibiotic treatment options.  A  prerequisite to the success 
of a  pharmacogenetic screening tests is the development of simple, robust, cost-effective 
single HLA allele test that can be implemented in routine diagnostic laboratories.  In this 
study, we developed a simple, real-time  allele-specific PCR for typing the HLA-A*32:01 
allele. Four-hundred and fifty-eight DNA samples including thirty HLA-A*32:01-positive 
samples were typed by allele-specific PCR.  Compared to ASHI accredited sequence-based 
high-resolution, full allelic HLA typing, this assay demonstrates 100% accuracy, sensitivity 
of 100% (95% CI: 88.43% to 100%) and specificity of 100% (95% CI: 99.14% to 100%). 
The lowest limit of detection of this assay using the Power Up SYBR Green is 10 ng of 
template DNA. The assay demonstrates a sensitivity and specificity to differentiate HLA-
A*32:01 allele from closely related non-HLA-A*32 alleles and may be used in clinical 























Human leukocyte antigens (HLA) play a key role in the development of severe immune-
mediated adverse drug reactions (IM-ADRs) 1. Multiple phenotypically distinct IM-ADRs 
have been associated in particular with the carriage of specific HLA class I risk alleles 2.
HLA alleles are highly polymorphic genes and are mainly involved in antigen recognition as 
a trimolecular complex of MHC–Peptide–T-cell receptor. Thus, the presence of a specific 
HLA allele determines the repertoire of epitopes that can be presented, restricting the 
specificity of reacting T cells 3.
 
We recently reported a strong association between HLA-A*32:01 and vancomycin-induced 
drug reaction with eosinophilia and systemic symptos (DRESS) in patients of European 
ancestry and showed that approximately 20% of subjects xposed to vancomycin for more 
than 2 weeks can be expected to develop DRESS 4. Vancomycin is a widely used antibiotic 
for the treatment of frequently encountered serious Gram-positive bacterial infections, 
including methicillin resistant Staphylococcus aureus. In reports of life-threatening T-cell–
mediated reactions, such as  DRESS, vancomycin features prominently in causality and 
recent studies suggest that vancomycin is the most c mmon cause of antibiotic-related 
DRESS 5, 6. DRESS is a rare but potentially life-threatening T-cell–mediated and multi-
system disorder characterized by the delayed onset of fever, a widespread rash, white cell 
abnormalities, and the involvement of internal organs following administration of a drug 7, 8. 
The mortality rate of DRESS is up to 10% and long- term sequalae have been described up to 
4 years following acute disease 9. Given that vancomycin is often initiated empirically s part 
of combination therapy in an emergent setting of sever  infection and that DRESS typically 














antibiotic should not be delayed but that HLA-A*32:01 testing be ordered immediately and 
that consideration be given to substituting vancomycin for an alternative antibiotic if the test 
result returns  positive.  HLA-A*32:01 testing may also have diagnostic utility and assist in 
drug causality assignment in subjects who have sympto s in keeping with DRESS improving 
the safety of future antibiotic therapy. A single allele assay for HLA-A*32:01 with a 
turnaround time of less than two days would hence be of clinical utility and a potentially cost-
effective option to improve the safety of this  antibiotic that is in widespread global use. 
 
Conventional HLA typing is done by serological or sequence-specific typing methods such as 
PCR amplification with use of sequence-specific olig nucleotide probes (SSO) or sequence-
based typing (SBT) techniques. Standard serological approaches lack specificity, as 
commercially available monoclonal antibodies cross-react with different HLA alleles 10. HLA 
typing using SSO sometimes results in low resolution products that are unable to resolve 
some HLA alleles 11. HLA typing by SBT is able to resolve HLA alleles with high resolution 
but is comparatively expensive, requires specialized DNA sequencing equipment and a 
skilled operator for analysis, and is time-consuming to prepare and analyse results. This study 
tested the potential of using a simple and fast PCR assay that utilizes allele-specific PCR 
(AS-PCR). This AS-PCR method should be less susceptibl  to laboratory or analysis errors, 
and be easier and less expensive to implement as a clinical test for the presence and absence 
of carriage of HLA-A*32:01.  
 















DNA samples were drawn from the Vanderbilt BioVu which represents DNA linked to a de-
identified electronic health record. Genomic DNA is extracted from discarded EDTA blood 
samples using the Qiagen automated DNA purification k t (Qiagen Inc., USA). 
 The study population was selected from the Vanderbilt Electronic Systems for 
Pharmacogenomic Assessment (VESPA) cohort 12. For this study, 458 DNA samples from 
this databank were analyzed by AS-PCR/melting curve. These DNA samples from the 
VESPA cohort had previously undergone high resolutin, full allelic HLA typing by next-
generation sequencing and in depth genotyping with structured race assignment 13. DNA 
sample identity was blinded to the operator at the time of the validation of the assay. The 
DNA samples were of good quality with a mean DNA concentration of 50 ng/uL and a 
260/280 ratio over 1.7. For this assay, the DNA concentration of samples were normalized to 
a concentration of 25 ng/uL with sterile deionized water (Sigma, Cat# W3500). The study 
sample contained a good representation of the HLA-A*32:01 allele (n=30) with a broad range 
of HLA-A*32-closely related alleles as listed in Table 1. 
 
Primers 
 Primers (Table 2) were designed within the exon 2 of HLA-A locus. Exon 2 DNA sequences 
of HLA-A*32 group and other closest alleles (Table 1) from IMGT/HLA database were 
aligned with HLA-A*32:01:01 using the IMGT/ HLA alignment tool (IMGT/ HLA datab se: 
https://www.ebi.ac.uk/ipd/imgt/hla/align.html, last accessed on 8th March 2019). The forward 
primer is a locked nucleic acid primer (LNA) and contains the sequence unique to the allele 
groups HLA-A*32 (except A*32:04 and A*32:01:18), A*29 and A*74. The reverse primer 
contains the sequence of the HLA-A*32 group (except A*32:03) and of the HLA-A*25 allele 














A*32:03, A*32:04 and A*32:01:18, yielding a 157-bp product. HLA-A*29:13 allele is the 
only non-HLA-A*32 group allele that can be amplified with this primer s t combination.(Fig. 
1A). Alignments of exon 2 of all HLA-B and HLA-C alleles ( Fig.1B) show that no other class 
I alleles are targeted by this primer combination, except for HLA-B*07:27 and HLA-
C*06:02:15 which could potentially be amplified. However, there are quite a number of 
mismatches in the reverse primer and the frequency of these alleles is very low in the global 
population . Internal control primers were designed to amplify the highly conserved 
housekeeping gene galactosylceramidase (GALC; HGNC:4115), yielding a 352-bp product.  
 
Allele-Specific PCR for Detection of HLA-A*32:01 
The real-time PCR reaction contained 2uL (50 ng) of total DNA, 1X Power Up SYBR Green 
Master Mix (Thermo Fisher Scientific, Australia), 250 nM of each HLA-A*32 specific 
primer, and 50 nM of each GALC primer in a 10-µL final volume. The master mix was 
dispensed on a 96 or 384-well qPCR plate using the Mantis® Liquid Handler (Formulatrix®, 
MA) by using a high-volume chip. DNA samples were stamped on a 96- or 384-well qPCR 
plate straight from the DNA storage plates using the Biomek® FXP liquid handler (Beckman 
Coulter, Australia). 
The real-time PCR was performed in 96-or 384 well optical plates on Bio-Rad CFX96/384 
qPCR machine (Bio-Rad Laboratories, Australia) using the following cycling conditions: 
Initial denaturation at 96 °C for 6 min to allow polymerase activation, followed by 35 cycles 
at 96 °C for 30 seconds and 62 °C for 1 minute. This was followed by a melting curve cycle 
from 65 °C to 95 °C with 0.5 °C increment for 5 seconds. The conditions of the PCR, such as 
primer concentrations and cycling conditions, were optimized to enable a clear separation of 
both HLA-A*32 specific Tm peak compared to the internal control Tm peak during melt 















A standard AS-PCR was performed using the same reaction onditions as for the real-time 
PCR. The standard AS-PCR was performed in 96-well half skirt PCR plates (AXYGEN 
Scientific, Australia) on the Bio-Rad C1000 thermocycler (Bio-Rad Laboratories). PCR 
products were analyzed by electrophoresis on a 1% agarose gel containing 0.2 µg/mL 
ethidium bromide and run at 115V for 30 minutes at room temperature. The gel was 
visualized by a transilluminator (ChemiDoc XRS+, Bio-Rad Laboratories).   
 
Data Analysis 
Raw real-time PCR data were analyzed using CFX Manager Software 3.0 (Bio-Rad 
Laboratories). Statistical analyses for validation studies to calculate sensitivity, specificity, 
and confidence intervals were performed using GraphP d Prism 5.02 for Windows 
(GraphPad Software Inc., San Diego, CA). 
 
RESULTS 
To validate this HLA-A*32:01 typing assay, 458 samples previously typed using American 
Society for Histocompatibility and  Immunogenetics (ASHI) accredited sequence-based high-
resolution, full allelic HLA typing were analyzed using the real-time PCR with Power Up 
SYBR Green master mix. All 30 samples out of the 458 samples were accurately identified as 
positive for HLA-A*32:01 allele. 
 
Samples were called positive or negative for HLA-A*32:01 based on the presence or absence 
of  HLA-A*32:01 specific melt peaks. HLA-A*32:01-positive samples (n=30) showed two 
peaks at 88.5 ºC ± 0.0 ºC (mean ± standard error of the mean; range: 88.50 ºC to 88.50 ºC) for 














76.00 ºC to 76.50 ºC) for GALC. The other 428 non-HLA-A*32 samples showed a single peak 
at 76.07 ºC ± 0.01 ºC (mean ± standard error of the mean; range: 75.50 ºC to 76.50 ºC) for 
GALC (Fig. 2). No melting curves were detectable for the non-template negative controls 
(Table 3). 
 
For the standard AS-PCR, samples were called positive or negative based on the presence or 
absence of the HLA-A*32:01 specific PCR product after agarose gel electrophoresis. HLA-
A*32:01 positive samples showed two bands of 157-bp (HLA-A*32:01) and 352-bp (GALC). 
Non-HLA-A*32 samples showed only one band of 352-bp (GALC) (Fig. 2). No product was 
detectable for the non-template negative controls. Thus, the sensitivity and specificity of this 
assay for HLA-A*32:01 allele in these 458 DNA samples were 100% (95% CI: 88.43% to 
100%) and 100% (95% CI: 99.14% to 100%), respectively (Table 4). 
 
DISCUSSION  
This study describes a simple, fast, and inexpensiv PCR assay that utilizes AS-PCR with 
melt curve analysis for the detection of HLA-A*32:01 allele. By using a combination of 
primers that included a LNA forward primer, the HLA-A*32:01 allele was specifically 
amplified in a real-time PCR. The assay was both 100% sensitive and specific making it safe 
and appropriate for clinical use. The assay was able to exclude all non-HLA-A*32:01 alleles 
included in the validation of this study. It is worth mentioning that the primer set combination 
could amplify the HLA-A*29:13 allele. However the frequency of this allele is very low at 
around 0% in both Caucasian and African American population 
(http://www.allelefrequencies.net, last accessed on 8th  March 2019). 
In addition, alignments of exon 2 of all HLA-B and HLA-C alleles (Fig.1B) show that no 














HLA-C*06:02:15 which may be amplified. However, there are quite a number of mismatches 
in the reverse primer which may prevent their amplification. Futhermore, the frequency of 
these alleles is very low within the global population (http://www.allelefrequencies.net, last 
accessed on 15 January 2019). Samples were not found in our biorepository for the validation 
of  these two non- HLA-A alleles.  
Amplification of low-level nonspecific products in real-time PCR has been previously 
reported. The formation of these nonspecific products can be influenced  by annealing 
temperature, primer concentration, magnesium concentration, and DNA inputs 14.  In this 
optimized assay, non-specific amplification was not de ected. Also, a LNA primer that 
specifically target  HLA-A*32 alleles was used. The incorporation of a LNA prime into 
oligonucleotide primers provides an increase of specific binding strength for target DNA 
amplification 15. In addition, a commercial optimized real-time PCR master mix (Power Up 
SYBR Green master mix), which is reported to be formulated for maximum specificity and 
reproducibility, was used. The detection range for template DNA in this assay was between 
10 ng to 100 ng. However, the assay optimal DNA concentration was between 25 ng and 50 
ng.  
 
The specificity of the assay was assessed for only the HLA-A*32:01 allele. The primer set 
combination was designed to specifically amplify all HLA-A*32 alleles, except A*32:03, 
A*32:04 and A*32:01:18. Given the low frequency of other HLA-A*32 alleles (eg, A*32:02, 
A*32:03, A*32:04, and A*32:01:18), especially in those of European ancestry16 
(http://www.allelefrequencies.net, last accessed on 15 January 2019), other non-HLA-
A*32:01 alleles were not found in our biorepository of samples primarily from those of 
European ancestry. Notably, across the entire Vanderbilt BioVU cohort with imputed HLA 














represented 85% of this cohort. Furthermore, it is currently unknown whether HLA-A*32 
alleles other than HLA-A*32:01 are associated with vancomycin DRESS or whether there are 
associations between other HLA alleles and vancomycin DRESS in those of non-European 
ancestry. It is known for instance that the carriage rate of HLA-A*32:01 is approximately 2% 
to 3% in African Americans which is half that carried in European Americans. This would 
mean that if the positive predictive value is equivalent to the almost 20% in European 
Americans,  that approximately twice as many African Americans would need to be tested to 
prevent or pre-empt one case of vancomycin DRESS which is still a cost-effective ratio. It 
will be important to determine if alleles other than HLA-A*32:01 are associated with 
vancomycin DRESS in non-European race.   
 
As for previous associations between drug hypersensitivity and HLA alleles such as abacavir 
and HLA-B*57:01, an allele also primarily represented in those of European ancestry,  the 
association was specific for HLA-B*57:01 and to-date HLA-B*57:01 screening has a 100% 
negative predictive value for abacavir hypersensitivity. It has been shown that HLA-B*58:01, 
HLA-B*57:03, and HLA-B*57:02 which differ by as few as 2 amino acids in the antigen 
binding cleft are not associated with abacavir hypersensitivity 17. HLA-A*32:01 has a leucine 
at position 156 which is a key peptide binding residue which differs from the glutamine at 
156 for HLA-A*32:02 and HLA-A*32:03 (IPD-IMGT/HLA database; 
https://www.ebi.ac.uk/cgi-bin/ipd/imgt/hla/align.cgi; last accecced on 4 January 2019). On 
the other hand, it has been demonstrated that in some drug hypersensitivity phenotypes 
different alleles of the same family confer susceptibility to adverse drug reaction. This is the 
case of carbamazepine SJS/TEN in which in addition of the HLA-B*15:02 risk allele, 
members of the same HLA-B*75 serotype could also present CBZ to activate CD8+ T cells 














binding groove of HLA-B*15:02 were involved in the presentation of CBZ to CD8+ T cells. 
Asn63 which is shared by members of the B*75 family was the key residue to confer this 
specificity 18.   
 
High resolution HLA typing is performed by direct sequencing of HLA class I and class II 
sequences. Although sequence-based typing (SBT) remains the gold standard for HLA 
typing, it is significantly more expensive, requires significant expertise and labor, and has a 
longer turnaround time compared to this assay in terms of time, cost, and labor and remains 
the domain of specialty immunogenetics and transplat boratories. SBT also requires 
sophisticated equipment, highly-trained staff, and  robust informatics and quality assurance 
infrastructure which might not be available in most f the clinical settings. HLA typing by 
hybridization of PCR amplicon with sequence-specific oligonucleotide probes (SSO) is an 
alternative method, but this method shows low resolution typing 19.  
 
In comparison with current HLA typing methods in terms of time and cost, this HLA-
A*32:01 screening assay seems to be appropriate for use in clin cal settings. On the cost of 
reagents alone, our cost calculation shows that it cos s around 20 times less using this real-
time PCR assay in comparison to HLA typing by sequence based typing. Time for operator 
setup and analysis also favors this rapid real-time assay due to the higher number of steps 
required for sequence based typing.  A single sample can be typed for HLA-A*32:01 with a 
turnaround time of less than three hours, with lessthan one hour of operator hands-on time 
with real-time PCR, whereas sequence based typing such as Sanger sequencing has a 
turnaround of at least eight to 10 hours with three hours of hands-on time. Ideal batch scale 
for sequence based  typing is approximately 90 samples and adds 10 hours of data analysis 














minimal addition of operator time when robotic setup is available. In addition, the level of 
operator expertise and sophisticated sequencing equipment needed for NGS might not be 
available in most of the clinical settings.  
 
The assay described here appears to give both specificity and sensitivity of 100%, with the 
advantage of being very fast and cheaper compared to other HLA typing methods. The 
flexible methodology means that this could be set-up in a variety of specialty 
immunogenetics or non-specialty aboratory settings that have access to a PCR platform that 
can perform melting curve analysis. Those settings without qPCR platform can use the 
standard AS-PCR followed by agarose gel electrophoresis. Although limited testing was 
conducted on standard PCR machine with the Power Up SYBR green master mix followed 
by agarose gel electrophoresis analysis and gel visualization, this assay was found to 
successfully adapt in settings which do not have qPCR platform.  
 
The considerable reduction of operator manual handling of post PCR amplicon and 
manipulation of results also reduce the potential r sk of sample mix-up as well as 
contamination. Where testing a large number of samples is needed, the use of robotic liquid 
handling system for transferring master mixes and DNA samples could provide some benefits 
in reducing turnaround time and human errors. In cases where unusual melt curves are found 
due to poor purity of DNA or operator technical error, samples should be further evaluated by 
using conventional PCR genotyping or SBT or by obtaining another sample. However, such 
cases were not encountered during our validation experiments. 
 
Currently single allele assays exist or have been published for HLA-B*57:01, HLA-B*15:02, 














been advocated as a pre-prescription screening strategy with specific drugs and specific 
populations 26, 27. The association of HLA-A*32:01 and vancomycin DRESS has only been 
recently reported. Currently, we are unaware of the existence of other available PCR-based 
methods specifically for the detection of HLA-A*32:01.    
This study is therefore novel in both reporting a new single-allele test specific for HLA-
A*32:01 and also in proposing a new use approach to pharmacogenetic testing that is 
practical and convenient for both the clinician and the laboratory. Based on a prevalence of 
HLA-A*32:01 in population of predominant European ancestry of 6.8% and estimates from 
that approximately 20% of those carrying HLA-A*32:01 exposed to vancomycin for at least 
two weeks will develop vancomycin DRESS, it can be estimated that 75 patients would need 
to be tested for HLA-A*32:01 to prevent one case of DRESS.  Given the low cost and relative 
convenience of testing in this clinical context and the severe implications of DRESS, this 
number needed to test should be sufficient to justify testing from a cost-effectiveness 
standpoint in most populations with carriage frequenci s of HLA-A*32:01 similar to the 
population tested in this study. Furthermore, it would also be feasible to use this rapid-
turnaround single-allele assay as an ancillary diagnostic test in patients who have developed 
DRESS on multiple antibiotics including vancomycin. 
 
In conclusion, this AS-PCR is a fast and reliable mthod for typing the HLA-A*32:01 allele. 
This assay demonstrates the sensitivity and specificity needed for the assignment of the HLA-
A*32:01 allele but caution that these assay characteristics may not be maintained with any 
modification to the method. In addition as per our experience with  HLA-B*57:01, the 
development of an allele specific international quality assurance program will help minimize 
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Figure 1: Binding sites of the set of primers and comparison of the different allele sequences of 
the target region. Exon 2 DNA sequences of HLA-A*32 group and other closest alleles from 
IMGT/HLA database were aligned with HLA-A*32:01:01 using the IMGT/ HLA alignment tool 
(IMGT/ HLA database: https://www.ebi.ac.uk/ipd/imgt/hla/align.html, last accessed on 8th March 
2019). A-B: Primer positions are marked by dashed boxes. The solid arrows show the direction of  
the forward primer: HLA 32-88F and reverse primer: HLA032R2. A:  The forward primer: HLA 32-
88F: 5’-ACACGCAGTTCGTGCGGTT+T-3’ is a locked nucleic acid primer (locked at position 
180) and contains the sequence unique to the allele groups HLA-A*32 (except A*32:04 and 
A*32:01:18), A*29, and A*74. The reverse primer: HLA032R2: 5’-GAGCGCGATCCGCAGGC-3’ 
contains the sequence of the HLA-A*32 group (except A*32:03) and of the HLA-A*25 allele group. 
The combination of forward and reverse primers is specific for and amplify all HLA-A*32 alleles, 
except A*32:03, A*32:04, and A*32:01:18. It is worth noting that  HLA-A*29:13 allele is the only 
non-HLA-A*32 group allele that can be amplified with this primer combination. B: Alignment of 
exon 2 of HLA-B and HLA-C alleles (IMGT/ HLA database) shows that only HLA-B*07:02:27 and 
HLA-C*06:15 may be amplified by this primer set combination; however, there are quite a number 
of mismatches within the reverse primer which may prevent the amplification. 
 
Figure 2: AS-PCR results. A: HLA-A*32:01-positive (+) and non-HLA-A*32 (-) samples were 
amplified by PCR using the following validated primers: HLA 32-88F forward primer and 
HLA032R2 reverse primer to amplify the HLA-A*32 allele. GALC-F and GALC-R primers were 
used to amplify the internal control housekeeping gene in a multiplexed reaction. PCR products were 
run on a 1% agarose gel containing 0.2 µg/mL ethidium bromide at 115V for 30 minutes. The gel 
was visualized by a transilluminator (ChemiDoc XRS+, Bio-Rad, Australia). HLA-A*32:01 positive 
samples show two bands of 157-bp (HLA-A*32:01 product) and 352-bp (GALC product). Non-HLA-














and GALC housekeeping gene are shown by a solid line arrow. Tm peaks for the HLA-A*32:01 
allele were clearly separate from the GALC Tm peak following melt curve analysis. C: Melting 
peaks for a subset of the 458 samples tested in a real-time PCR with Power Up SYBR Green are 
shown. Tm peaks of HLA-A*32:01 and non- HLA-A*32:01 alleles are shown by a solid line arrow.  
HLA-A*32:01-positive samples (n=30) show double Tm peaks at 88.5 ºC ± 0.0 ºC (mean ± standard 
error of the mean; range: 88.50 ºC to 88.50 ºC) for the HLA-A*32:01 allele and 76.05 ºC ± 0.03 ºC 
(mean ± standard error of the mean; range: 76.00 ºC to 76.50 ºC) for GALC. Non-HLA-A*32 allele 
samples show a single Tm peak at 76.07 ºC ± 0.01 ºC (mean ± standard error of the mean; range 























Table 1. HLA genotypes of samples eliminated by the present assay (HLA-A*32:01 AS-PCR). 
HLA-A specificities Number 
A*01:01 123 





































Table 2. Primer sequences for HLA typing of HLA-A*32:01 allele.  
Primer name Description Sequence (5´ to 3´)    Target  
HLA 32-88F HLA-A*32 forward primer  5´-GACGACACGCAGTTCGTGCGGTT+T-3´    HLA-A*32  
HLA 032R2 HLA-A*32 reverse primer 5´-GAGCGCGATCCGCAGGC-3´    HLA-A*32  
GALC-F: GALC forward primer 5´-TTACCCAGAGCCCTATCGTTCT-3´    GALC 


























Table 3. Melting curve analysis of HLA-A*32:01 and GALC amplicons. 
 
HLA alleles 
           Tm peaks  
HLA-A*32:01 GALC Amplicon length (bp) Validation 
HLA-A*32:01  88.5 76 157 Positive 
Non-HLA-A*32  None 76 352 Negative 






































HLA-A*32 Non-HLA-A*32 Total 
Positive 30 0 30 
Negative 0 428 428 


















































































 cDNA                 160        170        180        190        200        210        220        230        240        250        260        270        280        290        300        310        320 
 A*32:01:01    TACGTGGACG ACACGCAGTT CGTGCGGTTT GACAGCGACG CCGCGAGCCA GAGGATGGAG CCGCGGGCGC CGTGGATAGA GCAGGAGGGG CCGGAGTATT GGGACCAGGA GACACGGAAT GTGAAGGCCC ACTCACAGAC TGACCGAGAG AGCCTGCGGA TCGCGCTCCG 
 A*01:01:01    ---------- ---------- ---------C ---------- ---------- --A------- ---------- ---------- ---------- ---------- ---------- ---------- A--------- ---------- --------C- -A----G--- C-CT--G-G- 
 A*02:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------T ---------- -----GG--- ---------A ---------- ---------- -C------T- GA----G--- C-CT--G-G- 
 A*02:05:01    ---------- ---------- ---------C ---------- ---------G ---------- ---------- ---------- ---------T ---------- -----GG--- ---------A ---------- ---------- -C------T- GA----G--- C-CT--G-G- 
 A*11:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -G-------- --------T- GA----G--- C-CT--G-G- 
 A*23:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----G---- ----G----A ---------- ---------- ---------- -A-------- ---------- 
 A*24:02:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----G---- ----G----A ---------- ---------- ---------- -A-------- ---------- 
 A*25:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- ---------- ---------- ---------- ---------- 
 A*26:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- ---------- --------C- -A----G--- C-CT--G-G- 
 A*29:01:01    ---------- ---------- ---------- ---------- ---------- ---------- --------A- ---------- ---------- ---------- ------T-C- ---------- ---------- -G-------- --------C- -A----G--- C-CT--G-G- 
 A*29:13       ---------- ---------- ---------- ---------- ---------- ---------- --------A- ---------- ---------- ---------- ------T-C- ---------- ---------- -G-------- ---------- ---------- ---------- 
 A*30:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- -------A-- --T------- ---------- ---------- ---------- -G-------- --------T- GA----G--- C-CT--G-G- 
 A*31:01:02    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- -------A-- --T------- ---------- ---------- ---------- ---------T --------T- GA----G--- C-CT--G-G- 
 A*32:01:18    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- 
 A*32:02       ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- 
 A*32:03       ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -A-------- ---------- 
 A*32:04       ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- 
 A*32:05       ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----G----A ---------- ---------- ---------- ---------- ---------- 
 A*33:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- ---------T --------T- GA----G--- C-CT--G-G- 
 A*66:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- -G-------- --------T- GA----G--- C-CT--G-G- 
 A*68:01:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- -G-------- --------T- GA----G--- C-CT--G-G- 
 A*68:02:01    ---------- ---------- ---------C ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------G-A- C--------- ---------- -G-------- --------T- GA----G--- C-CT--G-G- 
 A*74:01:01    ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- --------T- GA----G--- C-CT--G-G- 
  HLA 32-88F                                                                                                                                                                  HLA032R2 
                                                                                                                                                                                 
 
  HLA 32-88F                                                                                                                                                          HLA032R2 
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 A*32:01:01    TACGTGGACG ACACGCAGTT CGTGCGGTTT GACAGCGACG CCGCGAGCCA GAGGATGGAG CCGCGGGCGC CGTGGATAGA GCAGGAGGGG CCGGAGTATT GGGACCAGGA GACACGGAAT GTGAAGGCCC ACTCACAGAC TGACCGAGAG AGCCTGCGGA TCGCGCTCCG 
 B*07:02:27    ---------- ----C----- ----A----- ---------- -------T-C ---AGA---- ---------- ---------- ---------- ---------- ------G-A- C----A--TC TAC------- -GG------- ---------- ---------- A-CT--G-G- 
































HLA-A*32:01 specific peak 
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